

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF DONG-E-E-JIAO FOR THE SIX MONTHS ENDED 30 JUNE 2026

On 20 August 2026, Dong-E-E-Jiao released its interim report for the six months ended 30 June 2026.

Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (“**Dong-E-E-Jiao**”) is a company incorporated in the People’s Republic of China. The shares of Dong-E-E-Jiao are listed on the Shenzhen Stock Exchange. As of the date of this announcement, Dong-E-E-Jiao is directly held as to 10.26% of its equity interests by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and approximately 23.66% is held by the Company through its non-wholly owned subsidiary, China Resources Dong-E-E-Jiao Company Limited (華潤東阿阿膠有限公司). The Group effectively controls approximately 23.66% of Dong-E-E-Jiao. Dong-E-E-Jiao is accounted for as a subsidiary of the Company.

On 20 August 2026, Dong-E-E-Jiao released its interim report for the six months ended 30 June 2026 (the “**Dong-E-E-Jiao Unaudited Financials**”). Set out below is the key financial information of the Dong-E-E-Jiao Unaudited Financials:

	As of 30 June 2026 (RMB) (unaudited)	As of 31 December 2025 (RMB) (audited)	Decrease (%)
Total assets	12,706,264,068.67	13,381,200,012.41	-5.04%
Net assets attributable to shareholders of the listed company	10,158,536,554.08	10,336,303,915.94	-1.72%

	For the six months ended 30 June 2026 (RMB) (unaudited)	2025 (RMB) (unaudited) (Restated)	Increase/ Decrease (%)
Revenue	3,155,143,496.50	3,051,583,802.55	3.39%
Net profit attributable to the shareholders of the listed company	860,377,588.81	814,303,895.42	5.66%
Net profit attributable to the shareholders of the listed company (exclude extraordinary gains or losses)	819,872,358.90	784,148,198.44	4.56%
Net cash flow from operating activities	81,567,258.59	966,238,927.23	-91.56%
Basic earnings per share (RMB/share)	1.34	1.26	5.97%
Diluted earnings per share (RMB/share)	1.34	1.26	5.97%
			Increased by 0.43 percentage points
Weighted average return on net asset	8.12%	7.69%	

As determined by the board of directors of Dong-E-E-Jiao, Dong-E-E-Jiao proposed to distribute a cash dividend of RMB13.44 (inclusive of tax) for every 10 shares to all Dong-E-E-Jiao's shareholders based on the total share capital of Dong-E-E-Jiao on the date of equity distribution registration. Such proposal has been submitted for shareholders' approval at Dong-E-E-Jiao's 2026 annual general meeting.

The Dong-E-E-Jiao Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustment during the course of auditing. The financial information set out in this announcement is limited to Dong-E-E-Jiao only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the Dong-E-E-Jiao Unaudited Financials, please refer to the interim report for the six months ended 30 June 2026 published by Dong-E-E-Jiao on the website of the Shenzhen Stock Exchange (www.szse.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 20 August 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director; Mr. Cheng Jie and Mr. Liu Changan as executive Directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.